Immunotherapy of Allergy: Anergy, Deletion, and Immune Deviation

Curr Opin Immunol. 1998 Dec;10(6):640-5. doi: 10.1016/s0952-7915(98)80082-4.

Abstract

Decreased allergen-specific T cell proliferation and dysregulated cytokine synthesis accompany allergen immunotherapy, consistent with mechanisms of anergy and immune deviation. Recent studies emphasise the pivotal role of decreased T cell IL-4:IFN-gamma ratios. A landmark clinical trial of T cell epitope peptides for venom-immunotherapy shows efficacy and safety; murine models suggest intramolecular epitope-suppression inhibits responses to the whole allergen.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Clonal Anergy / immunology*
  • Humans
  • Hypersensitivity / therapy*
  • Immunotherapy
  • Peptides / immunology
  • Peptides / therapeutic use
  • T-Lymphocytes / immunology*

Substances

  • Peptides